Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 156

1.

Basal forebrain degeneration precedes and predicts the cortical spread of Alzheimer's pathology.

Schmitz TW, Nathan Spreng R; Alzheimer's Disease Neuroimaging Initiative..

Nat Commun. 2016 Nov 4;7:13249. doi: 10.1038/ncomms13249.

2.

Bayesian model reveals latent atrophy factors with dissociable cognitive trajectories in Alzheimer's disease.

Zhang X, Mormino EC, Sun N, Sperling RA, Sabuncu MR, Yeo BT; Alzheimer’s Disease Neuroimaging Initiative..

Proc Natl Acad Sci U S A. 2016 Oct 18;113(42):E6535-E6544.

3.

Morphometricity as a measure of the neuroanatomical signature of a trait.

Sabuncu MR, Ge T, Holmes AJ, Smoller JW, Buckner RL, Fischl B; Alzheimer's Disease Neuroimaging Initiative..

Proc Natl Acad Sci U S A. 2016 Sep 27;113(39):E5749-56. doi: 10.1073/pnas.1604378113.

4.

Polygenic risk of Alzheimer disease is associated with early- and late-life processes.

Mormino EC, Sperling RA, Holmes AJ, Buckner RL, De Jager PL, Smoller JW, Sabuncu MR; Alzheimer's Disease Neuroimaging Initiative..

Neurology. 2016 Aug 2;87(5):481-8. doi: 10.1212/WNL.0000000000002922.

PMID:
27385740
5.

Early role of vascular dysregulation on late-onset Alzheimer's disease based on multifactorial data-driven analysis.

Iturria-Medina Y, Sotero RC, Toussaint PJ, Mateos-Pérez JM, Evans AC; Alzheimer’s Disease Neuroimaging Initiative..

Nat Commun. 2016 Jun 21;7:11934. doi: 10.1038/ncomms11934.

6.

A semi-mechanism approach based on MRI and proteomics for prediction of conversion from mild cognitive impairment to Alzheimer's disease.

Liu H, Zhou X, Jiang H, He H, Liu X; Alzheimer’s Disease Neuroimaging Initiative..

Sci Rep. 2016 Jun 7;6:26712. doi: 10.1038/srep26712.

7.

Effect of CLU genetic variants on cerebrospinal fluid and neuroimaging markers in healthy, mild cognitive impairment and Alzheimer's disease cohorts.

Tan L, Wang HF, Tan MS, Tan CC, Zhu XC, Miao D, Yu WJ, Jiang T, Tan L, Yu JT; Alzheimer’s Disease Neuroimaging Initiative..

Sci Rep. 2016 May 27;6:26027. doi: 10.1038/srep26027.

8.

Accelerating rates of cognitive decline and imaging markers associated with β-amyloid pathology.

Insel PS, Mattsson N, Mackin RS, Schöll M, Nosheny RL, Tosun D, Donohue MC, Aisen PS, Jagust WJ, Weiner MW; Alzheimer's Disease Neuroimaging Initiative..

Neurology. 2016 May 17;86(20):1887-96. doi: 10.1212/WNL.0000000000002683.

PMID:
27164667
9.

The impact of PICALM genetic variations on reserve capacity of posterior cingulate in AD continuum.

Xu W, Wang HF, Tan L, Tan MS, Tan CC, Zhu XC, Miao D, Yu WJ, Jiang T, Tan L, Yu JT; Alzheimer’s Disease Neuroimaging Initiative Group..

Sci Rep. 2016 Apr 27;6:24480. doi: 10.1038/srep24480.

10.

Better verbal memory in women than men in MCI despite similar levels of hippocampal atrophy.

Sundermann EE, Biegon A, Rubin LH, Lipton RB, Mowrey W, Landau S, Maki PM; Alzheimer's Disease Neuroimaging Initiative..

Neurology. 2016 Apr 12;86(15):1368-76. doi: 10.1212/WNL.0000000000002570.

PMID:
26984945
11.

The effect of increased genetic risk for Alzheimer's disease on hippocampal and amygdala volume.

Lupton MK, Strike L, Hansell NK, Wen W, Mather KA, Armstrong NJ, Thalamuthu A, McMahon KL, de Zubicaray GI, Assareh AA, Simmons A, Proitsi P, Powell JF, Montgomery GW, Hibar DP, Westman E, Tsolaki M, Kloszewska I, Soininen H, Mecocci P, Velas B, Lovestone S; Alzheimer's Disease Neuroimaging Initiative., Brodaty H, Ames D, Trollor JN, Martin NG, Thompson PM, Sachdev PS, Wright MJ.

Neurobiol Aging. 2016 Apr;40:68-77. doi: 10.1016/j.neurobiolaging.2015.12.023.

PMID:
26973105
12.

Amyloid negativity in patients with clinically diagnosed Alzheimer disease and MCI.

Landau SM, Horng A, Fero A, Jagust WJ; Alzheimer's Disease Neuroimaging Initiative..

Neurology. 2016 Apr 12;86(15):1377-85. doi: 10.1212/WNL.0000000000002576.

PMID:
26968515
13.

Alzheimer's Disease Assessment Scale-Cognitive subscale variants in mild cognitive impairment and mild Alzheimer's disease: change over time and the effect of enrichment strategies.

Podhorna J, Krahnke T, Shear M, Harrison JE; Alzheimer’s Disease Neuroimaging Initiative..

Alzheimers Res Ther. 2016 Feb 12;8:8. doi: 10.1186/s13195-016-0170-5.

14.

Reference tissue normalization in longitudinal (18)F-florbetapir positron emission tomography of late mild cognitive impairment.

Shokouhi S, Mckay JW, Baker SL, Kang H, Brill AB, Gwirtsman HE, Riddle WR, Claassen DO, Rogers BP; Alzheimer’s Disease Neuroimaging Initiative..

Alzheimers Res Ther. 2016 Jan 15;8:2. doi: 10.1186/s13195-016-0172-3.

15.

Periventricular hyperintensities are associated with elevated cerebral amyloid.

Marnane M, Al-Jawadi OO, Mortazavi S, Pogorzelec KJ, Wang BW, Feldman HH, Hsiung GY; Alzheimer's Disease Neuroimaging Initiative..

Neurology. 2016 Feb 9;86(6):535-43. doi: 10.1212/WNL.0000000000002352.

PMID:
26747881
16.

Highly adaptive tests for group differences in brain functional connectivity.

Kim J, Pan W; Alzheimer's Disease Neuroimaging Initiative..

Neuroimage Clin. 2015 Oct 22;9:625-39. doi: 10.1016/j.nicl.2015.10.004.

17.

Does posterior cingulate hypometabolism result from disconnection or local pathology across preclinical and clinical stages of Alzheimer's disease?

Teipel S, Grothe MJ; Alzheimer´s Disease Neuroimaging Initiative..

Eur J Nucl Med Mol Imaging. 2016 Mar;43(3):526-36. doi: 10.1007/s00259-015-3222-3.

PMID:
26555082
18.

MRI-based brain atrophy rates in ADNI phase 2: acceleration and enrichment considerations for clinical trials.

Hua X, Ching CR, Mezher A, Gutman BA, Hibar DP, Bhatt P, Leow AD, Jack CR Jr, Bernstein MA, Weiner MW, Thompson PM; Alzheimer's Disease Neuroimaging Initiative..

Neurobiol Aging. 2016 Jan;37:26-37. doi: 10.1016/j.neurobiolaging.2015.09.018.

19.

A potential endophenotype for Alzheimer's disease: cerebrospinal fluid clusterin.

Deming Y, Xia J, Cai Y, Lord J, Holmans P, Bertelsen S, Holtzman D, Morris JC, Bales K, Pickering EH, Kauwe J, Goate A, Cruchaga C; Alzheimer's Disease Neuroimaging Initiative..

Neurobiol Aging. 2016 Jan;37:208.e1-9. doi: 10.1016/j.neurobiolaging.2015.09.009.

PMID:
26545630
20.

Trajectories of Neuropsychiatric Symptoms and Cognitive Decline in Mild Cognitive Impairment.

David ND, Lin F, Porsteinsson AP; Alzheimer's Disease Neuroimaging Initiative..

Am J Geriatr Psychiatry. 2016 Jan;24(1):70-80. doi: 10.1016/j.jagp.2015.06.001.

PMID:
26525995
Items per page

Supplemental Content

Loading ...
Support Center